Related Experiment Video
Updated: Jan 21, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
[New slow-release buprenorphine formulations for optimization of opioid substitution]
Michael Soyka1,2, Oliver Pogarell3
1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, LMU München, München, Deutschland. m.soyka@medicalpark.de.
Abstract:
Opioid maintenance treatment with methadone or buprenorphine is an established first-line treatment for opioid dependence. In addition to the novel weekly and monthly subcutaneously injectable buprenorphine depot CAM 2038 (Buvidal®), which is already available in Germany, two other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade™) and a 6-month buprenorphine depot implant (Probuphine™). Basic pharmacological and clinical data of these three medications are given and possible clinical applications are discussed.
More Related Videos
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Receptors: Overview
Gene Evolution - Fast or Slow?
In contrast, regions which code...
Gene Evolution - Fast or Slow?
Opioid Analgesics: Morphine and Other Natural Cogeners
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

